One Global Service Provider Limited (formerly **Overseas Synthetics Limited**) is a **BSE-listed** entity (since **1994**) that has undergone a radical strategic pivot. Originally focused on industrial processing, the company has transitioned into a diversified provider of **Healthcare Services**, **Clinical Diagnostics**, and **IT & Software Solutions**. By operating at the intersection of digital health and technology consulting, the company aims to reduce per capita medical expenditure through a "One-Stop Solution" model. --- ### **Strategic Amalgamation & Corporate Transformation** The company’s current scale is the result of a transformative merger with **Plus Care International Private Limited (PCIPL)**, which was finalized via the **NCLT Mumbai Bench** on **March 25, 2025**. This merger shifted the company from a standalone entity to a comprehensive healthcare infrastructure provider. **Key Merger Details:** * **Appointed Date:** January 19, 2023. * **Share Exchange Ratio:** **1202** equity shares of OGSPL issued for every **1** share of PCIPL. * **Total New Shares Issued:** **1,24,38,296** Equity Shares. * **Asset Acquisition:** The merger integrated a network of **pathological labs, diagnostic centers, blood banks, and hospitals** into the listed entity’s portfolio. * **Promoter Reclassification:** In **March 2026**, **Sanjay Upadhaya** (holding **4,22,095 shares**) was formally reclassified into the **Promoter Group**. --- ### **Core Business Verticals** #### **1. Healthcare Services & Diagnostics** The company functions as a centralized provider for the medical ecosystem, focusing on **Accuracy, Affordability, and Accessibility**. * **Clinical Operations:** Management of hospitals, nursing homes, and diagnostic centers. * **Mass Screening:** Specialized expertise in large-scale public health screening and laboratory support for government bodies and eminent hospitals. * **R&D:** Active involvement in research and development related to medicines and physiological testing. #### **2. Digital Healthcare Supply Chain** OGSPL operates a "One-Stop Solution" online platform designed to bridge the gap between global manufacturers and end-users. * **Medical Devices & Equipment:** High-precision diagnostic tools and durable healthcare machinery. * **Consumables & Reagents:** Daily-use disposables and chemical substances required for laboratory diagnosis. * **Value Proposition:** Streamlining the supply chain to deliver world-class products directly to healthcare providers. #### **3. IT & Software Solutions** Launched in **2022**, this segment provides consultancy across the full software development lifecycle (**Design, Develop, Test, Integrate, Deploy, Maintain**). * **Tech Stack:** Specialization in **AI, Machine Learning, Data Analytics, and Cloud Computing**. * **Sector Diversification:** Serves Banking, E-commerce, Education, Biotechnology, and Infrastructure. * **Hardware Support:** Provision of **servers and routers** to host proprietary and client applications. --- ### **Financial Performance & Capital Structure** The post-merger financial profile shows a significant expansion in revenue and a strengthened balance sheet. | Particulars (Rs. in Lakhs) | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Total Revenue** | **14,704.17** | **6,301.11** | - | | **Profit After Tax (PAT)** | **1,846.66** | **710.88** | - | | **Total Equity** | **7,172.42** | **1,439.99** | **729.11** | | **Total Debt** | **3,460.20** | **1,740.69** | **553.40** | | **Debt-Equity Ratio** | **0.48** | **1.21** | **0.76** | **Capital Metrics:** * **Authorized Capital:** **INR 25,05,00,000**. * **Paid-up Capital:** Increased to **INR 19,54,30,030** post-merger (from **INR 7,10,47,070**). * **Solvency:** The **Debt-Equity Ratio** improved to **0.48**, reflecting a healthier capital mix despite higher absolute debt levels. * **Subsidiaries:** The company currently has **no subsidiaries, joint ventures, or associate companies**. --- ### **Governance & Institutional Framework** The company maintains a high standard of corporate governance, exceeding several statutory requirements. * **Board Independence:** **75% Independent Directors**, including **two Independent Woman Directors**, ensuring robust oversight. * **Risk Oversight:** A **Risk Management Committee** has been **voluntarily formed**, despite the company not being among the top 500 listed entities where this is mandatory. * **Compliance Note:** As of **September 2025**, the company noted a vacancy for the **Chief Financial Officer (CFO)** position (vacant since **March 16, 2024**), which is a pending regulatory requirement under **SEBI LODR**. --- ### **Market Growth Drivers & Strategic Outlook** * **Public Health Tailwinds:** The company is positioned to benefit from the **12.9% increase** in India’s **Union Budget 2024-25** for Health and Family Welfare (**Rs. 90,958.63 crore**). * **Operational Synergies:** The integration of PCIPL allows for the rationalization of administrative expenses and the pooling of technical human capital. * **Global Ambitions:** Targeting international markets for software products and healthcare solutions through organic growth and potential future acquisitions. * **Financial Flexibility:** Utilizing combined cash flows to fund expansion into preventive and precision medicine. --- ### **Risk Matrix & Mitigation** | Risk Category | Description | Mitigation/Status | | :--- | :--- | :--- | | **Supply Chain** | **80%** of APIs are imported from **China**, creating price and supply volatility. | Diversifying supplier base and focusing on integrated diagnostic reagents. | | **Regulatory** | Government **price capping** on medicines and margin pressures from state health schemes. | Focusing on high-volume mass screening and technology-driven services. | | **Credit Risk** | Potential for counterparty default in healthcare services. | Maintaining a diverse customer base with credit periods of **14 to 90 days**; concentration risk is **Low**. | | **Human Capital** | High dependency on specialized doctors and nurses. | Implementing retention strategies and leveraging AI to augment diagnostic efficiency. | | **Liquidity** | Managing obligations across a growing infrastructure footprint. | Board-approved framework utilizing a mix of internal accruals and optimized borrowings. |